ReviewMolecular oncology2021
Circulating tumor cell profiling for precision oncology.
Review in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic role of circulating tumor cells in gastric cancer: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.Frontiers in oncology · 2026Review
- Clinical relevance of perioperative changes in circulating tumor cells in resectable colorectal cancer.BMC cancer · 2025Article
- Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis.The Journal of clinical investigation · 2025Article
- Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer.BMC medicine · 2025Article
- Candidate Biomarkers Associated With Circulating Tumor Cell Status in Metastatic Colorectal Cancer.Journal of clinical laboratory analysis · 2025Article
- Advances in microfluidic platforms for tumor cell phenotyping: from bench to bedside.Lab on a chip · 2025Review
- Detection of circulating hybrid cells and circulating tumor cells in cerebrospinal fluid for leptomeningeal metastasis diagnosis and therapeutic prediction.Frontiers in cell and developmental biology · 2025Article
- Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer.Discover oncology · 2024Article
- The integrated on-chip isolation and detection of circulating tumour cells.Sensors & diagnostics · 2024Review
- Review
- Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies.Lab on a chip · 2024Review
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Advances in single-cell RNA sequencing and its applications in cancer research.Journal of hematology & oncology · 2023Review
- Electrical detection of RNA cancer biomarkers at the single-molecule level.Scientific reports · 2023Article
- Circulating tumour cell isolation, analysis and clinical application.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells.Cancer medicine · 2023Article
- Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range of opportunities in the field of precision oncology. With new advances in profiling technology, it is now possible to demonstrate an association between the molecular profiles of CTCs and tumor response to therapy. In this Review, we discuss mechanisms of tumor resistance to therapy and their link to phenotypic and genotypic properties of CTCs. We summarize key technologies used to isolate and analyze CTCs and discuss recent clinical studies that examined CTCs for genomic and proteomic predictors of responsiveness to therapy. We also point out current limitations that still hamper the implementation of CTCs into clinical practice. We finally reflect on how these shortcomings can be addressed with the likely contribution of multiparametric approaches and advanced data analytics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.